Palatin Technologies, Inc. (PTN)
12.82
-0.02
(-0.16%)
USD |
NASDAQ |
Sep 03, 16:00
13.34
+0.52
(+4.06%)
After-Hours: 20:00
Palatin Technologies Research and Development Expense (Annual) : 14.90M for June 30, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2025 | 14.90M |
| June 30, 2024 | 22.40M |
| June 30, 2023 | 22.63M |
| June 30, 2022 | 21.33M |
| June 30, 2021 | 12.93M |
| June 30, 2020 | 13.96M |
| June 30, 2019 | 14.86M |
| June 30, 2018 | 32.57M |
| June 30, 2017 | 45.68M |
| June 30, 2016 | 43.07M |
| June 30, 2015 | 24.56M |
| June 30, 2014 | 10.83M |
| June 30, 2013 | 10.53M |
| June 30, 2012 | 13.81M |
| Date | Value |
|---|---|
| June 30, 2011 | 10.38M |
| June 30, 2010 | 12.29M |
| June 30, 2009 | |
| June 30, 2008 | |
| June 30, 2007 | |
| June 30, 2006 | |
| June 30, 2005 | |
| June 30, 2004 | |
| June 30, 2003 | |
| June 30, 2002 | 12.12M |
| June 30, 2001 | 10.11M |
| June 30, 2000 | 9.110M |
| June 30, 1999 | 8.720M |
| June 30, 1998 | 7.112M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Decoy Therapeutics, Inc. | 0.3682M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |